Centrient Boosts Statins API Capacity
Centrient Pharmaceuticals has started its expanded production of statins at its manufacturing plant for active pharmaceutical ingredients (APIs) in Toansa, India. With the start-up of its second unit at the site, the Dutch company said it has doubled capacity for Atorvastatin and Rosuvastatin, meeting the increased demand for its sustainably produced portfolio.
Statins are currently the most prescribed drug class globally for the treatment of high cholesterol and cardiovascular diseases and among the top-selling drugs worldwide. Markets for Atorvastatin and Rosuvastatin in particular have shown steady growth in the past years, due to the continued global prevalence of high cholesterol issues, replacement of older generation statins and genericization of the market, Centrient said.
The Rotterdam-based company, once part of DSM Sinochem Pharmaceuticals and currently owned by US private equity investor Bain Capital, has production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the US and Mexico.
Centrient regards itself as global leader in sustainable antibiotics, next-generation statins and anti-fungals. It claims also that its statins are among the most sustainably produced in the industry as it has eliminated harmful solvents and generates less waste. Its carbon footprint is 32% lower than at traditional manufacturers, the company claims.
Author: Dede Williams, Freelance Journalist
